Blood test predicts which patients with lung cancer will benefit from newly approved immunotherapy drug
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting response to a newly approved immunotherapy called tarlatamab. The findings, which are published in Cancer Discovery, could allow clinicians to easily and noninvasively determine which patients should receive the drug.
“Isolating cancer cells from the blood has tremendous potential to guide immune-related cancer therapies, and our group has created cutting edge ...